NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/02/2024
Back to search
Official data from USPTO
ORSHINA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ORSHINA
ST13
US500000097318817Class
1, 5, 42, 44
Filing
97318817
Registration
7342346
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
04/02/2024
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
03/18/2022
Registration date
04/02/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/02/2024
Last transaction
04/02/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
Neuherberg, DE
Examiner
CANTONE, KERI H
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
Representatives
Ryan D. Artis RIVERSIDE LAW LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in industry and sciencein particular reagents for labelling of biomoleculesreagents for tagging of biomolecules; reagents for non-medical purposes for visualization or detection of biomolecules; reagents for non-medical purposes for tagging of chemical entities or chemical molecules; reagents for non-medical purposes for generation of molecular constructstransfection reagentsreagents for gene editing; reagents for non-medical purposes for investigations in relation to tissue disorders; reagents for non-medical purposes for investigations in relation to fibrosis; reagents for non-medical purposes for investigations in relation to inflammatory disorders; diagnostic reagentsnot for medical or veterinary purposes; chemical reagent mixtures in kit formother than for medical or veterinary use; Kits comprising reagents for use in scientific researchin particular kits for labelling of biomolecules; kits for non-medical purposes for tagging of biomolecules comprising reagents for tagging of biomolecules; kits for non-medical purposes for visualization or detection of biomolecules comprising reagents for visualization or detection of biomolecules; kits for non-medical purposes for generation of molecular constructs comprising reagents for generation of molecular constructs; transfection kits comprising reagents for transfection of cells; kits for non-medical purposes for gene editing comprising reagents for gene editing; kits for non-medical purposes for investigations in relation to tissue disorders comprising reagents for investigations in relation to tissue disorders; kits for non-medical purposes for investigations in relation to fibrosis comprising reagents for investigations of fibrosis; kits for non-medical purposes for investigations in relation to inflammatory disorders comprising reagents for investigations of inflammatory disorders; diagnostic kits comprising diagnostic reagents for scientific or research use not for medical and veterinary purposes
Class 5
Pharmaceuticalsin particular pharmaceuticals for treating fibrosispharmaceuticals for treating lung diseasespharmaceuticals for treating inflammatory disorderspharmaceuticals for treating scars and scar formationpharmaceuticals for promoting tissue repair and/or tissue regenerationpharmaceuticals for wound healingwherein all aforementioned pharmaceuticals include small chemical moleculespeptidesproteinsnucleic acidscellular products and gene therapy products; Diagnostic reagentsfor medical and veterinary purposes
Class 42
Scientific and industrial research in particular in the biochemicaldiagnostic or pharmaceutical fields; Biochemical and pharmaceutical laboratory servicesin particular in the field of discovery and development of drugs for treating fibrosislung diseasesscarsdrugs for preventing scar formation or drugs for wound healingin the field of discovery of drugs for promoting tissue repair and/or tissue regeneration; Chemical and biochemical analysis of active ingredients in the field of drugs for treating fibrosislung diseasesscarsin the field of drugs for preventing scar formation or drugs for wound healingin the field of drugs for promoting tissue repair and/or tissue regeneration; Scientific research consultancyin particular with respect to drug discovery methodologies and systems for drug discovery and with respect to drug development methodologies and systems for drug development
Class 44
Diagnosis and treatment of fibrosislung diseasesscars or scar formation; Diagnosis and healing of wound; Diagnosis and healing being medical services of wounds; Medical treatment being tissue repair and/or tissue regeneration for treatment of inflammatory conditions; Treatment prediction and diagnostics in the field of medicine and veterinary medicine
Publications
History of USPTO decisions and trademark events.
18 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/16/2024
PUBO
PUBLISHED FOR OPPOSITION
01/16/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/27/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/01/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/01/2023
ALIE
ASSIGNED TO LIE
12/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/28/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
03/29/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
03/29/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/06/2023
GNRT
NON-FINAL ACTION E-MAILED
01/06/2023
CNRT
NON-FINAL ACTION WRITTEN
01/06/2023
DOCK
ASSIGNED TO EXAMINER
12/30/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/23/2022
NWAP
NEW APPLICATION ENTERED
03/22/2022
Continuous trademark protection
Get notified about every new filing that threatens ORSHINA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.